Three Value Stocks Priced Below Estimated Worth In November 2024

In This Article:

As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals and potential for recovery or growth despite broader market volatility.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Provident Financial Services (NYSE:PFS)

US$18.85

US$37.47

49.7%

Proya CosmeticsLtd (SHSE:603605)

CN¥97.24

CN¥194.47

50%

Arteche Lantegi Elkartea (BME:ART)

€6.10

€12.20

50%

Elica (BIT:ELC)

€1.725

€3.44

49.8%

Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT)

KWD0.395

KWD0.79

50%

Bangkok Genomics Innovation (SET:BKGI)

THB2.68

THB5.35

49.9%

BayCurrent Consulting (TSE:6532)

¥4902.00

¥9762.93

49.8%

Redcentric (AIM:RCN)

£1.20

£2.39

49.8%

Beijing LeiKe Defense Technology (SZSE:002413)

CN¥4.72

CN¥9.39

49.8%

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

US$273.91

US$546.14

49.8%

Click here to see the full list of 955 stocks from our Undervalued Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

argenx

Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China with a market cap of €32.98 billion.

Operations: The company generates revenue from its biotechnology segment, amounting to $1.91 billion.

Estimated Discount To Fair Value: 44.8%

argenx is trading significantly below its estimated fair value, with a valuation gap exceeding 20% based on discounted cash flow analysis. Recent FDA approval of VYVGART Hytrulo for CIDP and strong clinical trial results bolster its growth prospects. Despite notable insider selling, revenue is forecast to grow at 26.2% annually, outpacing the Belgian market's average, and earnings are expected to increase by 58.04% per year as profitability approaches within three years.

ENXTBR:ARGX Discounted Cash Flow as at Nov 2024
ENXTBR:ARGX Discounted Cash Flow as at Nov 2024

GFL Environmental

Overview: GFL Environmental Inc. provides non-hazardous solid waste management and environmental services in Canada and the United States, with a market cap of CA$22.84 billion.